BofA lowered the firm’s price target on BioMarin (BMRN) to $97 from $102 and keeps a Buy rating on the shares. The firm’s lowered target reflects competitive headwinds to Voxzogo partly offset by risk-adjusted sales from label expansion into the hypochondroplasia indication, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
- BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
- Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin
- BioMarin reports Q4 non-GAAP EPS 46c, consensus 56c
- BioMarin sees 2026 non-GAAP EPS $4.95-$5.15, consensus $5.33